Ernexa says ERNA-101 plus anti-PD-1 clears tumors in ovarian cancer preclinical study

Eterna Therapeutics

Eterna Therapeutics

ERNA

0.00
  • Ernexa reported independent CRO validation of ERNA-101 combined with anti-PD-1 in an ovarian cancer model.
  • Combination produced complete tumor clearance with durable survival in 10 of 15 animals (67%).
  • No complete responses seen in 45 animals across ERNA-101 alone, anti-PD-1 alone, or untreated control groups.
  • Company kept timeline for IND submission in Q3 2026.
  • First-in-human Phase 1 trial expected to start in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150750PRIMZONEFULLFEED9762444) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.